Caught in a Covid-19 maelstrom, Eli Lilly locks down clinical trials as multibillion-dollar R&D ops derail
The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.
The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”
The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.